

Exhibit 99.1

# Third Quarter 2009 Webcast

October 28, 2009

**Alcon**<sup>®</sup>



# Safe Harbor Statement

*This presentation, made on October 28, 2009, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and are subject to a number of uncertainties and risks as detailed in the company's form 20-F filed with the SEC on March 17, 2009.*

*In addition, this presentation may include several financial measures, to assist in better understanding our business, that are not prepared in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures will be reconciled at the end of this presentation or in associated public information filed with the SEC.*

*Reports noted above are available on our website at [www.alcon.com](http://www.alcon.com) in the "Investors and Media" section. For further information contact the Alcon Investor Relations Department at (817) 551-8805.*

# **Business Overview**


**Kevin Buehler**

**President and Chief Executive Officer**

# Delivering Solid Financial Results


## Q3 Sales

(dollars in millions)



## Q3 Operating Income

(dollars in millions)




\*Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth is provided at the end of this presentation.

# Balanced Global Growth

## Global Sales by Product Line


*(dollars in millions)*



\*Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth is provided at the end of this presentation.

# U.S. Pharmaceutical Category Growth Improving


## U.S. Prescription Change for Key Categories vs. Prior Year



Source: WK Health (August YTD Data)

# Prostaglandin Category Indicating a Recovery

## U.S. Prostaglandin Prescription Change vs. Prior Year




Source: WK Health



# U.S. Cataract Procedure Growth is Rising


U.S. Cataract Procedure Growth



Source: MarketScope




# Strong Global Advanced Technology IOL Sales



# AcrySof® IQ ReSTOR® +3.0 Drives PC-IOL Gains

## U.S. PC-IOL Market Share

U.S. market share has increased 950 basis points since Q4 2008 on strength of IQ ReSTOR® +3.0



Source: Market Scope

# Commercial Execution Driving Market Share Gains

<u>RX Growth</u>	Global**		U.S.	
	August YTD		August YTD	
	Brand	Market	Brand	Market
TRAVATAN® Family	23.8 %	7.2 %	22.6%	4.4%
Azopt® + Azarga®	13.4%	8.6%	10.9%	9.7%
Vigamox® *	9.7%	1.6%	-3.1%	-3.0%
NEVANAC®	74.4%	1.7%	9.0%	8.5%
Patanol® + Pataday™	23.8%	8.7%	-1.8%	-2.5%
CIPRODEX® *	4.6%	0.8%	1.5%	-2.7%

Source: Global-IMS US-WK Health


\* Moxifloxacin, the active ingredient in **Vigamox**®, is licensed to Alcon by Bayer HealthCare AG. **CIPRODEX**® is a registered trademark of Bayer AG and licensed to Alcon by Bayer HealthCare AG.

\*\* Top 30 countries

# TRAVATAN® Family Leads Global Glaucoma Gains

## Alcon Global Prostaglandin Market Share

TRAVATAN® Family has gained 6.5 share points following DuoTrav™ and TRAVATAN Z® launches




■ TRAVATAN® ■ TRAVATAN Z® ■ DUOTRAV™


Source: IMS

# Long-Term Opportunity in International Markets

Developed International Organic Growth\*



Emerging Market Organic Growth\*



Reported Growth    8.6%    19.9%    18.0%    -0.6%

21.0%    21.3%    21.5%    -4.6%




\*Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth is provided at the end of this presentation.

# Phaco Key to Emerging Markets Success

## Emerging Market LAUREATE® Unit Sales

LAUREATE® units sold through Q3 2009 are 41% over full-year 2008 unit sales



Source: Company data

# Transforming Research and Development

- Build on core capabilities of pharmaceutical formulation and biomedical engineering to select and develop new technologies and molecular entities into eye therapies
- Develop further abilities to deliver both breakthrough and incremental therapies
- Focus on selected disease conditions based on their segment value, scientific understanding of their causality and the unmet medical need
  - Preferentially target specific mechanisms of action and technologies that are validated in terms of linkage to clinical effects

# Financial Review

**Rick Croarkin**

**Senior Vice President, Finance and Chief Financial Officer**




# Sales

## Q3

(dollars in millions)

**+5.9% Reported**

**+9.0% Organic Growth\***




## YTD

(dollars in millions)

**-0.3% Reported**

**+5.6% Organic Growth\***




\*Organic sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic sales growth is provided at the end of this presentation.

# Gross Profit

## Q3

(dollars in millions)

+3.3%




% of Sales      77.2%                      75.3%

## YTD

(dollars in millions)

-0.5%




% of Sales      75.8%                      75.6%

# Operating Income

## Q3

(dollars in millions)

+17.0%




% of Sales  
32.4%

35.8%

## YTD

(dollars in millions)

+5.1%




% of Sales  
34.2%

36.0%

# Net Earnings

## Q3 Reported


(dollars in millions, except EPS)



% of Sales  
41.1%

## Q3 Adjusted

(dollars in millions, except EPS)



% of Sales  
25.4%      32.0%




NOTE: Adjusted diluted EPS and net earnings measures the results of the company's operations without certain items that pertain only to the period presented. Management believes this measure is an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Net Earnings

## YTD Reported


(dollars in millions, except EPS)



% of Sales      33.8%

## YTD Adjusted

(dollars in millions, except EPS)



% of Sales      28.8%      32.7%



NOTE: Adjusted diluted EPS and net earnings measures the results of the company's operations without certain items that pertain only to the period presented. Management believes this measure is an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# 2009 Full Year Financial Guidance Revision

- Organic growth in the mid-single digits
- Diluted earnings per share:

<b>U.S. GAAP EPS guidance</b>	<b>\$6.55 - \$6.65</b>
<i>Add back restructuring charge</i>	<i>\$0.05      \$0.05</i>
<b>Adjusted EPS guidance</b>	<b>\$6.60 - \$6.70</b>

NOTE: Adjusted diluted EPS measures the results of the company's operations without certain items that pertain only to the period presented. Management believes this measure is an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Third Quarter 2009 Webcast

October 28, 2009

**Alcon**<sup>®</sup>



# Q3 2009 Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES

### Global Sales (USD in millions)

	Three Months Ended September 30,		Change	Foreign Currency Change	Organic Change
	2009	2008			
<b>Geographic Sales</b>					
<b>Alcon United States:</b>					
Pharmaceutical	\$ 324	\$ 301	7.6 %	-- %	7.6 %
Surgical	304	275	10.5	--	10.5
Consumer Eye Care	105	105	--	--	--
<b>Total United States Sales</b>	<b>733</b>	<b>681</b>	<b>7.6</b>	<b>--</b>	<b>7.6</b>
<b>Alcon International:</b>					
Pharmaceutical	335	308	8.8	(7.4)	16.2
Surgical	435	417	4.3	(4.1)	8.4
Consumer Eye Care	111	118	(5.9)	(5.9)	--
<b>Total International Sales</b>	<b>881</b>	<b>843</b>	<b>4.5</b>	<b>(5.6)</b>	<b>10.1</b>
<b>Total Global Sales</b>	<b>\$ 1,614</b>	<b>\$ 1,524</b>	<b>5.9</b>	<b>(3.1)</b>	<b>9.0</b>
<b>Global Product Sales</b>					
Infection/inflammation	\$ 199	\$ 208	(4.3) %	(3.8) %	(0.5) %
Glaucoma	286	242	18.2	(3.7)	21.9
Allergy	97	85	14.1	(1.2)	15.3
Otic/nasal	106	86	23.3	(1.1)	24.4
Other pharmaceuticals/rebates	(29)	(12)	N/M	N/M	N/M
<b>Total Pharmaceutical</b>	<b>659</b>	<b>609</b>	<b>8.2</b>	<b>(3.8)</b>	<b>12.0</b>
Intraocular lenses	278	256	8.6	(2.7)	11.3
Cataract/vitreoretinal	436	408	6.9	(2.2)	9.1
Refractive	25	28	(10.7)	(3.6)	(7.1)
<b>Total Surgical</b>	<b>739</b>	<b>692</b>	<b>6.8</b>	<b>(2.4)</b>	<b>9.2</b>
Contact lens disinfectants	119	119	--	(1.7)	1.7
Artificial tears	73	73	--	(5.5)	5.5
Other	24	31	(22.6)	(3.2)	(19.4)
<b>Total Consumer Eye Care</b>	<b>216</b>	<b>223</b>	<b>(3.1)</b>	<b>(3.1)</b>	<b>--</b>
<b>Total Global Sales</b>	<b>\$ 1,614</b>	<b>\$ 1,524</b>	<b>5.9</b>	<b>(3.1)</b>	<b>9.0</b>

N/M - Not Meaningful

Note: Organic change calculates sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission. Certain reclassifications have been made to prior year amounts to conform to current year presentation.





# Q3 2009 Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES

### Global Sales

(USD in millions)

	Nine Months Ended September 30,		Change	Foreign Currency Change	Organic Change
	2009	2008			
<b>Geographic Sales</b>					
<b>Alcon United States:</b>					
Pharmaceutical	\$ 1,022	\$ 1,027	(0.5) %	-- %	(0.5) %
Surgical	858	805	6.6	--	6.6
Consumer Eye Care	301	309	(2.6)	--	(2.6)
<b>Total United States Sales</b>	<b>2,181</b>	<b>2,141</b>	<b>1.9</b>	<b>--</b>	<b>1.9</b>
<b>Alcon International:</b>					
Pharmaceutical	976	956	2.1	(11.3)	13.4
Surgical	1,311	1,353	(3.1)	(10.0)	6.9
Consumer Eye Care	316	346	(8.7)	(11.0)	2.3
<b>Total International Sales</b>	<b>2,603</b>	<b>2,655</b>	<b>(2.0)</b>	<b>(10.7)</b>	<b>8.7</b>
<b>Total Global Sales</b>	<b>\$ 4,784</b>	<b>\$ 4,796</b>	<b>(0.3)</b>	<b>(5.9)</b>	<b>5.6</b>
<b>Global Product Sales</b>					
Infection/inflammation	\$ 609	\$ 667	(8.7) %	(5.4) %	(3.3) %
Glaucoma	793	705	12.5	(6.9)	19.4
Allergy	400	384	4.2	(1.5)	5.7
Otic/nasal	285	256	11.3	(2.0)	13.3
Other pharmaceuticals/rebates	(89)	(29)	N/M	N/M	N/M
<b>Total Pharmaceutical</b>	<b>1,998</b>	<b>1,983</b>	<b>0.8</b>	<b>(5.4)</b>	<b>6.2</b>
Intraocular lenses	815	805	1.2	(6.9)	8.1
Cataract/vitreoretinal	1,276	1,263	1.0	(6.0)	7.0
Refractive	78	90	(13.3)	(5.5)	(7.8)
<b>Total Surgical</b>	<b>2,169</b>	<b>2,158</b>	<b>0.5</b>	<b>(6.3)</b>	<b>6.8</b>
Contact lens disinfectants	341	356	(4.2)	(3.4)	(0.8)
Artificial tears	208	209	(0.5)	(9.6)	9.1
Other	68	90	(24.4)	(6.6)	(17.8)
<b>Total Consumer Eye Care</b>	<b>617</b>	<b>655</b>	<b>(5.8)</b>	<b>(5.8)</b>	<b>--</b>
<b>Total Global Sales</b>	<b>\$ 4,784</b>	<b>\$ 4,796</b>	<b>(0.3)</b>	<b>(5.9)</b>	<b>5.6</b>

N/M - Not Meaningful

Note: Organic change calculates sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission. Certain reclassifications have been made to prior year amounts to conform to current year presentation.



# Q3 2009 Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures

	Net earnings		
	Q3 2009	Q3 2008	Growth
As Reported	\$ 515	\$ 627	(17.9) %
2008 Tax Benefit	--	(240)	
2009 restructuring adjustment	1	--	
As Adjusted	<u>\$ 516</u>	<u>\$ 387</u>	33.3 %

Note: Adjusted net earnings measures the results of the company's operations without certain items that pertained only to the period presented. Management believes these measures are an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

	Reported Change	Foreign Currency Change	Organic Change
BRIC nation sales	0.6 %	( 12.7) %	13.3 %
Global advanced technology intraocular lens sales	34.2 %	( 3.5) %	37.7 %

Note: Organic change presents sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

2009 reported	\$ 6.55-6.65
2009 restructuring adjustment	0.05
2009 adjusted	<u>\$ 6.60-6.70</u>

Note: Adjusted net earnings and diluted EPS measure the results of the company's operations without certain items that pertained only to the period presented. Management believes these measures are an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Q3 2009 Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Earnings (Unaudited) (in millions, except share data)

	Three months ended 9/30/09			Three months ended 9/30/08		
	Reported	09 RIF	Adjusted	Reported	08 Tax	Adjusted
Net earnings	\$ 515	\$ 1	\$ 516	\$ 627	\$ (240)	\$ 387
Net earnings growth	(17.9)%		33.3%			
Basic earnings per common share	\$ 1.72	\$ 0.01	\$ 1.73	\$ 2.10	\$ (0.80)	\$ 1.30
Diluted earnings per common share	\$ 1.71	\$ --	\$ 1.71	\$ 2.07	\$ (0.79)	\$ 1.28

## ALCON, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Earnings (Unaudited) (in millions, except share data)

	Nine months ended 9/30/09			Nine months ended 9/30/08		
	Reported	09 RIF	Adjusted	Reported	08 Tax	Adjusted
Net earnings	\$ 1,549	\$ 14	\$ 1,563	\$ 1,623	\$ (240)	\$ 1,383
Net earnings growth	(4.6)%		13.0%			
Basic earnings per common share	\$ 5.19	\$ 0.04	\$ 5.23	\$ 5.44	\$ (0.80)	\$ 4.64
Diluted earnings per common share	\$ 5.15	\$ 0.05	\$ 5.20	\$ 5.38	\$ (0.79)	\$ 4.58

# Q3 2009 Non-GAAP Reconciliations

	Reported Change	Foreign Currency Change	Organic Change
<b><u>Developed International Organic Growth</u></b>			
2006	8.6%	0.1	8.5%
2007	19.9	8.3	11.6
2008	18.0	9.5	8.5
2009 YTD	(0.6)	(8.0)	7.4
Q3 2009	7.4	(2.0)	9.4
<b><u>Emerging Market Organic Growth</u></b>			
2006	21.0	2.2	18.8
2007	21.3	5.2	16.1
2008	21.5	3.4	18.1
2009 YTD	(4.6)	(15.7)	11.1
Q3 2009	(0.7)	(12.0)	11.3

Note: Constant currency sales growth rate calculates sales growth without the impact of foreign exchange fluctuations. Organic sales growth rates calculate sales growth without the impact of foreign exchange and acquisition fluctuations. Management believes constant currency sales growth and organic sales growth are important measures of the company's operations because they provide investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices and acquisitions. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Q3 2009 Non-GAAP Reconciliations

	Reported Change	Foreign Currency Change	Organic Change
Japan Glaucoma Sales	49.3%	19.4	29.9%

Note: Constant currency sales growth rate calculates sales growth without the impact of foreign exchange fluctuations. Organic sales growth rates calculate sales growth without the impact of foreign exchange and acquisition fluctuations. Management believes constant currency sales growth and organic sales growth are important measures of the company's operations because they provide investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices and acquisitions. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

# Q2 2009 Non-GAAP Reconciliations

## ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures

	<u>Change</u>	<u>Foreign Currency Change</u>	<u>Organic Change</u>
Global advanced technology intraocular lens sales	30.1 %	( 8.2) %	38.3 %

Note: Organic change presents sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.